Sanyou Biopharmaceuticals Signs Strategic Deal With Baiyunshan Xihe to Co‑Develop Novel Radiopharmaceuticals
Sanyou Biopharmaceuticals (Shanghai) Co., Ltd. and Guangzhou Baiyunshan Xihe Health Medicine Co., Ltd. announced the...
PIC
IMPACT Therapeutics Signs Exclusive Deal With Pharmanovia for Senaparib PARP Inhibitor Across 66 Countries Worth Up to EUR 423.5 Million
IMPACT Therapeutics, Inc. (HKG: 7630) announced an exclusive partnership with Pharmanovia for senaparib (brand name:...
CanSino Biologics Reaches Cooperation Intent With Pakistan’s AGP Limited on PCV13i Pneumococcal Vaccine
CanSino Biologics (HKG: 6185) announced that it reached a cooperation intent with its Pakistani partner...
GRIT Biotechnology and Drug Farm Sign Deep Collaboration Agreement to Co‑Create KunEvo, an AI‑Native Biotech R&D Platform for First‑in‑Class Drug Discovery
GRIT Biotechnology and Sino-US biotech company Drug Farm jointly announced a deep agreement to collaborate...
Hangzhou Eli Radiopharma and Shanghai Smartlogic Sign Strategic Cooperation Agreement to Advance Computation‑Driven Radiopharmaceutical Discovery and Co‑Build Cyclic Peptide Platform
Hangzhou Eli Radiopharma Co., Ltd. and Shanghai Smartlogic Technology Ltd. officially signed a strategic cooperation...
BeOne Medicines Announces Imdelltra (Tarlatamab), First-in-Class DLL3/CD3 T-Cell Engager Co-Developed With Amgen, Enters Clinical Use Across 17 Chinese Cities
BeOne Medicines Ltd. (NASDAQ: ONC; HKG: 6160; SHA: 688235) announced that Imdelltra (tarlatamab for injection)...
Xtalpi and Gan & Lee Pharmaceuticals’ AI Peptide Delivery Lab Recognized as Beijing Key Laboratory, Deepening AI‑Powered Peptide Drug R&D Collaboration
XtalPi Inc. (HKG: 2228) and Gan & Lee Pharmaceuticals (SHA: 603087) announced that their jointly...
Hopstem Biotech Completes First Close of Nearly RMB 200 Million Series C to Advance iPSC Cell Therapy Pipeline Led by hNPC01
Hopstem Biotechnology announced the completion of the first close of its nearly RMB 200 million...
Kelun-Biotech Signs Commercialization Deal With New Frontier Health for Sacituzumab Tirumotecan in Hong Kong and Macao
Kelun-Biotech (HKG: 6990) announced a strategic commercialization agreement with New Frontier Health Technology, a subsidiary...
WuXi AppTec Wins Preliminary Injunction Against DoD 1260H Designation
WuXi AppTec Co., Ltd. (SHA: 603259, HKG: 2359) announced that the U.S. District Court for the District...
Grand Pharma’s GPN01530-2 RDC Drug Snags FDA Fast Track for Solid Tumor Diagnosis
Grand Pharmaceutical Group Limited (HKG: 0512) announced that GPN01530-2, a global innovative radionuclide drug conjugate (RDC)...
Daiichi Sankyo Enlists Innovent Biologics as Exclusive China Partner for Vanflyta FLT3 Inhibitor in AML
Daiichi Sankyo Co., Ltd. (TYO: 4568) and Innovent Biologics, Inc. (HKG: 1801) announced an exclusive entrusted promotion...
Takeda Expands Revestive Approval in China with New 1.25 mg Specification for Pediatric Short Bowel Syndrome Patients as Young as 4 Months
Takeda Pharmaceutical Company Limited (TYO: 4502; NYSE: TAK) announced that China’s National Medical Products Administration...
Westlake Consortium Secures NMPA Approval for Iscartrelvir, Novel Oral 3CLpro Inhibitor for Mild-to-Moderate COVID-19
The Category 1 innovative drug Iscartrelvir, jointly developed by Westlake University, Westlake Laboratory, and Westlake...
Merck Secures FDA Acceptance for Enflonsia sBLA to Expand RSV Prevention Through Second Season in High-Risk Children
Merck & Co., Inc. (MSD, NYSE: MRK) announced that the U.S. Food and Drug Administration...
Gilead Sciences Reports Q2 2026 Revenue of $7.8B, Driven by HIV Franchise and Trodelvy Growth Despite Cell Therapy Decline
Gilead Sciences, Inc. (NASDAQ: GILD) announced second-quarter 2026 financial results with total revenues of USD...
Astellas Reports Record Q1 FY2026 Revenue of ¥640.9B, Driven by Strategic Brands Growth and Raises Full-Year Outlook
Astellas Pharma Inc. (TYO: 4503) announced first-quarter fiscal year 2026 financial results featuring revenue of...
Takeda Receives FDA Approval for ORZEYFUL (oveporexton), First Oral OX2R Agonist for Narcolepsy Type 1 in Adults
Takeda Pharmaceutical Company Limited (TYO: 4502; NYSE: TAK) announced that the U.S. Food and Drug...
Eli Lilly Reports Record Q2 2026 Revenue of $22.97B, Driven by Tirzepatide Blockbusters and Raises Full-Year Guidance
Eli Lilly and Company (NYSE: LLY) announced second-quarter 2026 financial results featuring revenue of USD...
BeOne Medicines Reports Record Q2 2026 Revenue of $1.7B, Driven by Brukinsa Growth and Raises Full-Year Guidance
BeOne Medicines Ltd. (NASDAQ: ONC, HKG: 6160, SHA: 688235) announced Q2 2026 financial results featuring...